<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02982395</url>
  </required_header>
  <id_info>
    <org_study_id>DPMBLC301</org_study_id>
    <nct_id>NCT02982395</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC</brief_title>
  <official_title>A Phase Ⅲ Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M (Docetaxel-PM) In Bacillius Calmette-Guerin Refractory Non-Muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of
      patients with recurrent Ta and T1 who experienced treatment failure with at least one prior
      BCG intravesical treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free rate</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrence free rate will be summarized as the percentage of participants who achieved a confirmed recurrence free as assessed by urine cytology and cystoscopy. Recurrence means reappearance of high-risk disease (high grade, T1 or CIS) after the start of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free rate</measure>
    <time_frame>6 months, 2 years</time_frame>
    <description>Recurrence free rate will be summarized as the percentage of participants who achieved a confirmed recurrence free as assessed by urine cytology and cystoscopy.Recurrence means reappearance of high-risk disease (high grade, T1 or CIS) after the start of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from random assignment to death resulting from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse event (AE) is as any AE occurring or worsening from the first treatment of any study drug to the last dose of the last study drug. Severity grades according to NCI CTCAE version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Non Muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Nanoxel®M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg in 100mL normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg in 100mL normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanoxel®M</intervention_name>
    <description>Intravesical</description>
    <arm_group_label>Nanoxel®M</arm_group_label>
    <other_name>Polysorbate 80, ethanol free Docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C</intervention_name>
    <description>Intravesical</description>
    <arm_group_label>Mitomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of superficial transitional cell carcinoma of the
             bladder (Ta, T1)

          -  Recurrent superficial bladder cancer refractory to Bacillus Calmette-Guerin (BCG)

          -  No previous intravesical therapy for 6 weeks

          -  No history of prior radiation to the pelvis

          -  Peripheral neuropathy ≤ grade 1

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 t0 2

          -  Adequate hematopoietic and hepatic parameters

        Exclusion Criteria:

          -  Muscle invasive disease (T2-T4)

          -  Any other malignancy diagnosed within 2 years of study entry (Except basal or squamous
             cell skin cancers or noninvasive cancer of the cervix)

          -  Participation in any other research protocol involving administration of an
             investigational agent within 3 months before study entry

          -  History of sensitivity reaction to docetaxel

          -  Prescribed immunosuppressive medications because of a confounding medical condition

          -  Female patients who were pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ja Hyeon Ku</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miryung Jin</last_name>
    <phone>+82-2-2157-9842</phone>
    <email>miryung.jin@samyang.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ja Hyun Ku, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ja Hyun Ku, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nanoxel M</keyword>
  <keyword>Docetaxel PM</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Mitomycin C</keyword>
  <keyword>BCG</keyword>
  <keyword>BCG refractory</keyword>
  <keyword>Non muscle invasive bladder cancer</keyword>
  <keyword>intravesical</keyword>
  <keyword>superficial bladder cancer</keyword>
  <keyword>Urothelial carcinoma</keyword>
  <keyword>Transitional cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

